CM Life Sciences III Inc.

CM Life Sciences III Inc. is a healthcare-focused special purpose acquisition company that completed its initial public offering in 2021, sponsored by CM Life Sciences, an entity affiliated with Casdin Capital and Foresite Capital. The SPAC merged with EQRx, a biopharmaceutical company focused on developing and commercializing lower-cost medicines, and traded publicly under the ticker EQRX on Nasdaq. In September 2023, the company filed a DEFM14A — a definitive proxy statement — indicating a subsequent merger or acquisition event requiring shareholder approval, reflecting continued corporate activity in the life sciences sector following its original de-SPAC combination. Sign up at SpacDesk for full filing history, timeline data, and analytics on EQRX and hundreds of other SPAC transactions.